Larvol Delta - Bright-Peak-Therapeutics-Announces-Dosing-of-First-Patient-in-Phase-12a-Clinical-Trial-of-BPT567-a-FirstinClass-Bifunctional-PD1IL18-Immunoconjugate

BPT567 - Bright Peak Therap

https://www.globenewswire.com/news-release/2024/10/17/2964792/0/en/Bright-Peak-Therapeutics-Announces-Dosing-of-First-Patient-in-Phase-1-2a-Clinical-Trial-of-BPT567-a-First-in-Class-Bifunctional-PD1-IL18-Immunoconjugate.html

Oct 17, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next